US › Healthcare

Oramed Pharmaceuticals Inc (ORMP)

US · Healthcare · Biotechnology

$4.07-2.63%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$78.2M

Profit YoY

+488.2%

EPS

$-0.09

EPS estimate

$0.43

EPS came in at -0.09 against a street estimate of 0.43 — a miss of 120.9%.

Key statistics

Market cap

$172.2M

P/E

1.0

Forward P/E

0.0

P/B

0.62

Book value

$7.68

EPS (TTM)

$4.13

52-week high

$5.47

52-week low

$1.95

50-day MA

$4.65

200-day MA

$3.97

Beta

1.28

Analyst view

with an average price target of $7.00.

Shareholding

Insiders

21.27%

Institutions

45.14%

Largest institutional holders

Fund	Stake
Mercer Global Advisors Inc.	9.16%
Aquamarine Financial (Cayman) Ltd	6.04%
Gem Investment Advisors, LLC	4.81%
BlackRock Inc	3.87%
Murchinson Ltd.	3.10%
BML Capital Management LLC	2.08%
BOOTHBAY FUND MANAGEMENT, LLC	1.39%
Geode Capital Management, LLC	1.20%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oramed Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.